Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Progyny, a leader in fertility and family building benefits, will have its CEO Pete Anevski and CFO Mark Livingston engage in a fireside chat at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 10:30 A.M. Eastern Time. This event will be accessible via a live audiocast on Progyny’s website. The company’s innovative solutions are designed to empower patients and reduce healthcare costs for employers while achieving optimal clinical outcomes. Progyny is headquartered in New York City and has received numerous recognitions for its growth and leadership in the healthcare sector.
Summary not available.
Progyny (Nasdaq: PGNY) has launched the AHA Grant™ in partnership with The Broken Brown Egg, aiming to provide education, financial assistance, and emotional support to individuals and couples of color facing infertility. Announced on May 6, 2022, the grant will support one recipient with financial aid for treatment, medication through partners like Alto Pharmacy and Ferring Pharmaceuticals, and guidance from a dedicated fertility coach. Applications are open until June 10, 2022, with the winner revealed in mid-July.
Progyny, Inc. (PGNY) reported record revenue of $172.2 million for Q1 2022, marking a 41% growth year-over-year. The company raised its full-year revenue guidance to $735 million to $775 million, anticipating 47% to 55% growth. Despite a 67% decline in net income to $5 million, adjusted EBITDA rose 44% to $24.8 million. Progyny experienced operational efficiencies, with a total of 264 clients and a significant increase in pharmacy benefit services revenue, reflecting a strong demand for fertility benefits.
Progyny (Nasdaq: PGNY), a leader in fertility benefits management, announced its executives will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 11:40 A.M. ET. The event will provide insights into their comprehensive fertility solutions aimed at improving patient care and reducing costs for employers. A live audiocast and replay will be available on Progyny's website. The company is noted for its innovative approach and recognition from various organizations, indicating its growth and leadership in the industry.
Progyny, Inc. (Nasdaq: PGNY) will release its financial results for Q1 2022 on May 5, 2022, after market close. A conference call will follow at 4:45 PM Eastern Time. Interested parties can join via phone or through a live webcast available on the company’s investor relations page. Progyny specializes in fertility benefits management, offering comprehensive solutions that enhance patient care while reducing employer healthcare costs. The company has gained recognition for its innovative approach and commitment to improving fertility solutions across the U.S.
Progyny, Inc. (PGNY) and RESOLVE: The National Infertility Association are set to highlight National Infertility Awareness Week 2022 by ringing the Nasdaq Opening Bell on April 26, 2022, and lighting the Empire State Building in orange on April 27, 2022. This initiative aims to raise awareness about infertility, affecting 1 in 8 couples in the U.S. CEO Pete Anevski emphasized Progyny's mission to support over 100,000 individuals in their family building journeys. The event seeks to eliminate stigmas associated with infertility and calls on employers and legislators to address the crisis.
Progyny (Nasdaq: PGNY), a top benefits management company in fertility and family building solutions, announced that CEO Pete Anevski and CFO Mark Livingston will engage in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 3:50 P.M. ET. This event aims to discuss Progyny's innovative approach to fertility benefits, highlighting its comprehensive solutions that benefit employers, patients, and physicians. A live audiocast and replay will be accessible on their official website.
Progyny, Inc. (PGNY) reported record revenues of $500.6 million for 2021, marking a 45% growth year-over-year. The fourth quarter revenue reached $127.6 million, up 27%, driven by a significant increase in clients. Despite the impact of the COVID-19 Omicron variant, the company maintained a high retention rate and successful sales season. However, net income in Q4 decreased to $15.1 million from $39.1 million the previous year, primarily due to a lower tax benefit. Looking ahead, 2022 guidance forecasts revenue of $730 million to $775 million, reflecting 46% to 55% growth.
Progyny, Inc. (Nasdaq: PGNY) will announce its financial results for the quarterly period and full year ending December 31, 2021, on February 28, 2022. A conference call will be held at 4:45 PM ET to discuss the results, with access details provided for U.S. and international participants. An audio replay will be available until March 7, 2022. Progyny specializes in fertility and family building benefits, focusing on education and access to specialists while reducing costs for employers. The company has received recognition for its growth and leadership in the sector.